The genXone’s President
dr Michał Kaszuba
e-mail for investors: ir@genxone.eu
“At genXone, we create solutions that are the future of medicine, science and business.
We have been operating since 2016, developing and promoting the opportunities offered by the nanopore sequencing technology developed by Oxford Nanopore Technologies. We believe that in just a few years, access to the molecular genetics tools will be at your fingertips and disease diagnostics, microorganisms identification or tracking the changes in the microbiome will be quick and cheap. “